Objective: To determine whether the association between overall survival (OS) and response to neoadjuvant chemotherapy (NACT) in breast cancer patients varies with tumor subtype and anatomic extent of pathologic complete response (pCR). Background: pCR after NACT predicts improved OS in breast cancer, but it is unclear whether pCR limited to the breast or axilla is also associated with OS. Methods: Women with cT1-3/cN0-1 breast cancer diagnosed in 2010 to 2014 who underwent surgery following NACT were identified in the NCDB and divided into 4 subtypes based on reported hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) status. Kaplan-Meier curves and Cox proportional hazards models were used to estimate OS. Multivariate logistic regression was used to identify factors associated with post-NACT response, defined as upstage (yp stage>clinical stage); no change (clinical stage ¼ yp stage); overall (breastþaxilla, ypT0N0), breast-only (ypT0N1/ N1mic), or node-only (ypT1-3N0) pCR.
I
n breast cancer patients, axillary node involvement at diagnosis has long been considered the most critical determinant of long-term prognosis. 1 Although this principle has historically been reflected in the anatomic stage/prognostic groupings published by the American Joint Committee on Cancer (AJCC), 2 it has become increasingly clear that other clinicopathologic characteristics also play an important role in determining the long-term outcomes of breast cancer patients. Grade, tumor biology, and genomic testing results are now considered in conjunction with tumor size and lymph node involvement to determine breast cancer stage in the most recent AJCC guidelines. 3 Furthermore, the development of highly effective human epidermal growth factor receptor 2 (HER2)-targeted therapy has significantly improved disease-free and overall survival (OS) among patients who overexpress HER2, including those presenting with node-positive disease. [4] [5] [6] [7] Neoadjuvant chemotherapy (NACT) has emerged as a treatment strategy in patients presenting with node-positive breast cancer and a means by which the morbidity of locoregional treatment can be reduced or avoided. Systemic therapy for breast cancer was initially administered in the adjuvant setting, but its potential role in the preoperative treatment of resectable patients started to gain traction in the 1990s. 8 NSABP B-18 and EORTC 10902 demonstrated the safety of administering neoadjuvant systemic therapy for nonmetastatic breast cancer, allaying concerns that preoperative systemic treatment would be associated with worse survival compared with adjuvant administration. 9, 10 NACT can downstage the primary breast tumor, potentially facilitating lumpectomy. Furthermore, NACT enables in vivo, presurgical observation of treatment efficacy. This observed clinical response can subsequently be confirmed or refuted via pathologic analysis of the surgical specimen. However, the efficacy of neoadjuvant treatment varies significantly between regimens and among different receptor subtypes.
Pathologic complete response (pCR), or the absence of invasive disease in the breast and lymph nodes, is the optimal outcome following NACT and is associated with improved survival. 9, [11] [12] [13] [14] [15] But there has been some evidence that even a partial response to NACT may significantly impact prognosis. 16, 17 More recently, the role of NACT as a means of downstaging the axilla has been further explored, both as a source of prognostic information and as a way to avert the morbidity of axillary lymph node dissections (ALNDs) and nodal irradiation in clinically node-positive patients. [16] [17] [18] [19] [20] [21] Yet, it remains unclear whether pCR that is anatomically limited to the breast or axilla confers clinically significant prognostic information that could potentially be used to assess the efficacy of novel agents in clinical trials or guide the clinical management and counseling of node-positive patients.
In this study, we sought to (1) establish rates of pCR -whether complete or limited to the breast and/or axilla -by breast cancer subtype and (2) determine whether achieving either full or anatomically limited (breast-only or axilla-only) pCR confers a survival benefit to node-positive patients, rendering their prognosis equivalent to that of patients who present with node-negative disease. We hypothesized that response to NACT, as demonstrated in previous smaller studies, has a greater impact on survival than extent of disease at presentation.
METHODS

Patient Cohort
Female patients age ! 18 years diagnosed with clinical tumor stage (cT) 1 to 3, clinical node stage 0 to 1 invasive breast cancer between 2010 and 2014, and who received surgery after NACT were identified from the National Cancer Data Base (NCDB). Clinical node (cN) stage is defined in the NCDB according to imaging studies (excluding lymphoscintigraphy), clinical examination demonstrating characteristics highly suspicious for malignancy, and/or pathologic diagnosis obtained via needle biopsy. Patients with noninvasive disease [ie, Stage 0 or ductal carcinoma in situ (DCIS)] at diagnosis or on post-NACT pathological review (ie, ypTis); cN2-3 disease; clinical or pathological stage M1 disease; missing stage information; no or unknown number of examined lymph nodes; a surgical procedure coded as ''none,'' ''local tumor destruction only,'' ''not otherwise specified,'' or ''unknown''; and/or missing survival information were excluded. Although some definitions of pCR allow for the presence of residual DCIS, we chose to exclude patients with pathological stage ypTis. This strict definition of complete pCR allowed us to minimize heterogeneity in our primary endpoint, given emerging evidence that ypTis may be associated with worse longterm outcomes than ypT0. 15 The cohort was divided into 4 subtypes based on combinations of hormone receptor (HR) and HER2 status, with HR-positive (HRþ) defined as estrogen receptor-positive (ERþ) and/or progesterone receptor-positive (PRþ), while HR-negative (HRÀ) was defined as ER-negative (ER-) and PR-negative (PR-): HRþ/HER2À, HRþ/HER2þ, HR-/HER2þ, and HR-/HER2À (ie, triple-negative). pCR was defined as the absence of any residual invasive carcinoma or DCIS on pathologic review of a surgical specimen following NACT. Response to NACT was categorized as (1) upstage (ie, a change from lower cT and/or cN stage to higher ypT and/or ypN stage); (2) no stage change (cTN ¼ ypTN); (3) overall pCR (ie, breastþaxilla, ypT0N0), (4) breast-only pCR (ypT0N1/N1mic), or (5) node-only pCR (ypT1-3N0). Breast-only and node-only pCR were only determined for patients who were clinically node-positive at diagnosis; clinically node-negative patients with no residual invasive disease on pathologic review were included in the overall (ie, breastþaxilla) pCR cohort.
It has already been shown that residual disease is, in general, associated with worse survival as compared with pCR. The focus of our analysis, however, was to determine whether anatomically limited pCR (which could also be thought of as anatomically segregated pCR with residual disease in a different compartment) is associated with survival when, compared with no change in stage and overall pCR. Thus, in order to simplify our statistical analysis and focus on the 3 forms of downstage (pCR in the breast, the axillary nodes, or both) in which we were primarily interested, we excluded cN1 patients who experienced breast or nodal downstaging without achieving pCR as well as cN1 patients who had discordant changes in breast and nodal stage (ie, breast underwent upstage while axilla was downstaged and vice versa) following NACT from our regression and survival analyses. We also excluded patients with an uncategorized response to NACT.
Statistical Analysis
Chi-square tests and analysis of variance (ANOVA) or Kruskal-Wallis tests, as appropriate, were used to assess differences in categorical and continuous variables, for which we report proportions and median values with interquartile ranges (IQRs), respectively. A generalized logistic regression model was used to estimate the associations between receptor subtype and post-NACT response after adjustment for clinicopathologic characteristics. This model was built in the generalized estimating equations framework and accounted for the correlation of patients treated at the same facility by incorporating an exchangeable correlation structure.
OS was defined as the time from diagnosis to death or last follow-up; as required by NCDB guidelines, patients diagnosed in 2014 were excluded from survival analyses due to insufficient length of follow-up. Kaplan-Meier (KM) curves were used to visualize unadjusted OS for the entire cohort as well as patients grouped by receptor subtype and clinical N stage, with log-rank P < 0.05 defined as significant. Cox proportional hazards modeling was used to estimate the association of receptor subtype and post-NACT response with OS after adjustment for known covariates including clinical T and N stage at presentation after we confirmed weak collinearity with post-NACT outcomes using the rule of Variance Inflation Factor (VIF) <10. 22 The supremum test was used to verify the proportional hazards assumption for the fully adjusted OS model. In order to determine whether the effect of response on survival differs based on receptor subtype, an adjusted Cox proportional hazards model including a responseÃsubtype interaction term was utilized. A robust sandwich covariance estimator was included in all Cox models to account for the correlation of patients treated at the same facility. We report hazard ratios and 95% confidence intervals (95% CIs) with 2-tailed P < 0.05 considered significant. All analyses were conducted using SAS version 9.4 (SAS Institute, Cary, NC) and R version 3.3.2 (R Foundation for Computing, Vienna, Austria). The Duke University institutional review board granted this study exempt status due to use of de-identified patient data.
RESULTS
We identified 33,162 female breast cancer patients (cN0 n ¼ 18,804, cN1 n ¼ 15,078) who underwent surgery following NACT between 2010 and 2014 ( Fig. 1, Table 1 ). Breastþaxilla pCR was achieved by 19.2% (n ¼ 6370) of patients, with similar rates among cN0 (18.2%, n ¼ 3284) and cN1 (20.5%, n ¼ 3086) patients. The highest rates of overall pCR occurred among those with the HR-/ HER2þ subtype (39.6%, n ¼ 1256) followed by the triple-negative subtype (26.5%, n ¼ 2611, P < 0.001, see Table 1 ). Among cN1 patients, 3.3% (n ¼ 494) of patients had breast-only pCR, with the highest rates again seen among HR-/HER2þ (5.1%, n ¼ 86) and triple-negative patients (4.2%, n ¼ 165, P < 0.001). 7.5% (n ¼ 1133) of cN1 patients experienced node-only pCR, but rates were fairly similar across subtypes and ranged from 7.1% (HRþ/HER2À) to 8.1% (HR-/HER2À). The HRþ/HER2À subtype had the highest proportion of patients without change in stage (33.7%) and with upstage (12.4%, P < 0.001). Rates of post-lumpectomy radiation were similar across subtypes, but among mastectomy patients with known radiation status, HRþ/ HER2À patients had the highest rates of post-mastectomy radiation (PMRT, 51.6%), while triple-negative patients had the lowest rates of PMRT (40.0%, P < 0.001). Clinically, node-negative patients had less extensive axillary surgery than cN1 patients regardless of receptor subtype, with 70% of cN0 patients having 5 or fewer nodes examined, while 51% of cN1 patients had 10 or more nodes examined (P < 0.001). Among the 4 subtypes, HRþ/HER2À patients had the greatest number of lymph nodes examined at surgery, with 6 or more lymph nodes examined in 50.1%, compared with 39% among triplenegative patients (P < 0.001). This finding remained significant when patients were separated by cN stage: 21% of cN0, HRþ/HER2À patients and 53.4% of the cN1, HRþ/HER2À patients had 10 or more nodes examined, while triple-negative patients had the lowest number of nodes retrieved, with only 12.5% of cN0 patients and 48.7% of the cN1 patients having 10 or more nodes examined. Among cN1 patients achieving pCR in the breast (n ¼ 3580), 86.2% (n ¼ 3086) also achieved pCR in the axillary nodes, but among those without breast pCR (n ¼ 5044), only 22.5% (n ¼ 1133) achieved nodal pCR, indicating an expected association between breast and nodal response (P < 0.001, Table 2 Those variables with VIFs < 10, that is, without collinearity, were included in the final multivariate model; cN and cT stage were not found to be collinear with treatment response and thus were included in the overall analyses but excluded from the subset analyses to avoid overfitting. Achieving overall pCR and node-only pCR (compared with no stage change) and having the HRþ/HER2þ subtype (compared with the HRþ/HER2À subtype) were associated with improved OS for the entire cohort. Having upstage, triple-negative subtype, highgrade disease, cT2 or cT3 stage, cN1 stage, more extensive axillary surgery (ie, greater number of lymph nodes removed and examined), and mastectomy were all associated with worse OS; black race/ ethnicity and not having private insurance were also associated with worse OS (Table 3) . When the analysis was stratified by cN status, improved survival continued to be associated with the HRþ/HER2þ (vs HRþ/HER2À) subtype and with overall pCR (vs no stage change) for both cN0 and cN1 patients; cN1 patients also saw improved survival with breast-only and node-only pCR, though the effect size was smaller for both than for breastþaxilla pCR (see SDC, Tables 3a  and 3b , http://links.lww.com/SLA/B465). There was a significant 
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FIGURE 2. Unadjusted overall survival in NCDB breast cancer patients following neoadjuvant chemotherapy and surgery -patients with overall and anatomically limited pCR (n ¼ 7997). When survival was examined within cohorts defined by both cN stage and receptor subtype, pCR was associated with improved survival for cN0 patients with all subtypes except HRþ/HER2þ, while upstaging was associated with worse survival for the HR-/ HER2þ (hazard ratio 2.31, 95% CI 1.13-4.74, P ¼ 0.02) and triplenegative subtypes (hazard ratio 2.19, 95% CI 1.59-3.02, P < 0.001, Table 4 ). Among cN1 patients, breast-only pCR was associated with improved OS only in triple-negative disease (hazard ratio 0.58, 95% CI 0.37-0.89, P ¼ 0.01), while node-only pCR was associated with improved OS in both triple-negative (hazard ratio 0.55, 95% CI 0.39-0.76, P < 0.001) and HRþ/HER2À disease (hazard ratio 0.54, 95% CI 0.33-0.89, P ¼ 0.02). In the fully adjusted OS model, the proportional hazards assumption held for pCR but did not hold for HR/HER2 receptor subtypes. As such, we have presented both the fully adjusted model with pCR and receptor subtypes as well as the adjusted models stratified by receptor subtype and cN stage (see SDC, Tables 4a-d, 5a-d, and 6a-d, http://links.lww.com/SLA/B465).
DISCUSSION
In this large, population-based study of patients undergoing NACT for breast cancer, rates of pCR in the breast, axilla, or both differ according to receptor subtype. We confirmed that pCR is associated with improved OS but found that the magnitude of its effect on survival is dependent on both receptor subtype and anatomic extent of pCR. Specifically, a subset of node-positive patients with breast-only or node-only pCR had improved survival compared with those experiencing no change in stage but had worse survival compared with those experiencing pCR in both the breast and axilla.
In keeping with our findings, in 2 institutional retrospective analyses 16, 17 and a pooled analysis of trial participants, 12 patients with persistently positive nodes following NACT had worse OS. Accordingly, breast-only pCR should be considered as distinct from 
Impact of Tumor Phenotype
Notably, anatomically limited pCR confers no significant survival advantage in HER2þ breast cancers. The improvement in survival achieved by the efficacy of HER2-targeted agents such as trastuzumab and pertuzumab has resulted in HER2þ patients' having the highest rates of pCR of any breast cancer subtype. 12, 13, 23, 24 Accordingly, any response to HER2-targeted therapy short of pCR in both the breast and lymph nodes signals poor prognosis, with OS comparable to that seen in patients with no response to NACT. Furthermore, upstage in HR-/HER2þ patients was observed in our study to be a significant negative prognosticator (Table 4) because it represents an uncommon and untoward response to what is typically highly effective treatment. In contrast, upstage following NACT was not associated with reduced OS in patients with HRþ/HER2À cancer, supporting the previously observed finding that long-term outcomes in these patients rely more on long-term response to endocrine treatment than to chemotherapy. 25 The HRþ/HER2þ subtype emerged as the group with the best survival, likely as a result of the many effective targeted treatment options -including endocrine therapy and HER2-directed therapyavailable to patients with this phenotype (Table 3) . As a result, however, pCR is less critical to these patients' long-term outcome, and, indeed, pCR was not associated with survival among cN0, HRþ/ HER2þ patients. This finding can be attributed to the limited number of events observed among these patients during the period of observation (Table 4) as well as the generally favorable prognosis of this group. In contrast, triple-negative and HRþ/HER2À patients have fewer, less effective systemic options for locally advanced disease. Accordingly, among HER2À patients, those experiencing any form of favorable response such as overall pCR or even breast-or node-only pCR have improved survival as compared to those who do not. These partial and complete responders represent a singular group, notable for having overcome relative chemoresistance (on the part of HRþ/HER2À disease) and inherently unfavorable biology (on the part of triple-negative disease) to demonstrate a favorable response to systemic therapy.
Impact of Surgery Extent
We also evaluated the impact of surgery on survival in our study cohort. We found that mastectomy was associated with worse adjusted OS, a finding observed in other population-based analyses. 26, 27 This association may, in part, be due to unmeasured variables that could not be adjusted for in the multivariate analysis: specifically, patients who receive mastectomy after systemic therapy may have worse disease at baseline as well as less evidence of a clinical response to neoadjuvant treatment, hence the decision to ultimately pursue mastectomy. Unfortunately, registries such as the NCDB do not capture the clinical assessment -including imaging and physical examination as well as patient preference and reconstructive concerns -that occurs after NACT but immediately before surgery. Although the focus of our study was to examine anatomically limited and overall pCR, our findings about the relationship between breast surgery type and OS highlight the extent to which the path from diagnosis to treatment completion is marked by milestones and decision nodes that are difficult to document and quantify but may nonetheless have as great an impact on survival as more concrete assessments such as whether and to what extent pCR is achieved. Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P Hazard Ratio (95% CI) P 
Implications for Future Research
Our findings come at a time of increased interest with regards to how pCR might be used to inform both research and clinical practice. In 2014, the results of the Collaborative Trials in Neoadjuvant Breast Cancer (CTNeoBC) pooled analysis were published. 12 This study was an international collaboration led by the United States Food and Drug Administration (FDA) and included 12 clinical trials and 11,955 patients. As with our study, the investigators reported that overall pCR in both the breast and nodes -but not when limited to the breast -was associated with better longterm outcomes and holds more promise as a potential surrogate for survival. Likewise, they concluded that pCR is strongly associated with survival and that rates of pCR were highest in triple-negative and HER2þ disease. Following this report, pCR has been used by the FDA as an endpoint to facilitate accelerated approval for agents such as pertuzumab, which was expeditiously approved after producing an 18% improvement in pCR as part of the NeoSphere trial. 5, 28, 29 Our study did not include trial-level data, but we were able to evaluate pooled, subtype-specific outcomes in over 20,000 patients. Importantly, our cohort was limited to an era in which trastuzumab had widespread use, thus avoiding the potential attenuation of effect size observed in studies such as CTNeoBC that included unidentified HER2þ patients who were not treated with HER2-targeted therapies. Our analysis confirms and further extends the findings of CTNeoBC by demonstrating that pCR in both the breast and axilla has the potential to be an effective clinical trial endpoint for all tumor subtypes, while the prognostic value of pCR in either the breast or nodes alone must be considered in the context of intrinsic tumor biology.
Limitations
The limitations of our study are the same as those pertaining to other retrospective analyses of the NCDB. Neither disease-specific mortality nor recurrence data are captured, so our assessments of long-term outcome were limited to OS. Pathologic response to NACT is reported by member institutions, but these assessments are not subjected to central pathologic review that might otherwise identify and reclassify cases for which the pathologic stage was incorrect. Before 2009, there was sparse coding of HER2 status in the NCDB; hence, we limited our analysis to patients diagnosed in 2010 and beyond; we did not include use of HER2-targeted therapy in our multivariate models given the high uptake of anti-HER2 treatment by 2010 and the collinearity of this covariate with HER2 status. However, we note that the data did not allow for identification of those patients treated with single-versus dual-agent HER2-targeted therapy, and limited chemotherapy data precluded any additional regimen-specific analyses. The HRþ/HER2À subtype was the reference group in our regression analyses, but we recognize that there is significant heterogeneity within this group and that associations with pCR and survival may align with other characteristics such as luminal type and genomic make-up that are not captured in our analysis.
We limited our analysis to cN0/1 patients because of the heterogeneity of anatomical nodal involvement in cN2/3 patients and our inability to assess achievement of pCR in nonaxillary nodal basins. Accordingly, caution should be used in applying our findings to patients with large-volume and/or nonaxillary nodal disease. In using the cutoffs of 1 to 5, 6 to 9, and !10 LNs to divide the cohort according to extent of axillary surgery, we are using a strategy employed by others given the coding limitations in the NCDB. 30, 31 We know that nodal yield is often lower after NACT and that the aforementioned category cutoffs represent yield rather than intent. Accordingly, it is possible that a higher number of ALNDs (for which !10 LNs has been used as a proxy) were performed than our data reflect but that <10 LNs were sometimes obtained even when axillary dissection was intended.
Finally, as previously described in the methods section, in order to simplify our statistical analysis and focus on the 3 forms of downstage in which we were primarily interested, we excluded cN1 patients who experienced breast or nodal downstaging without achieving nodal pCR as well as cN1 patients who had discordant changes in breast and nodal stage (ie, breast underwent upstage while axilla was downstaged and vice versa) following NACT. Patients who did not fall into the 5 post-NACT responses we defined represent a heterogeneous group for whom we did not feel we could provide definitive conclusions. The results of a sensitivity analysis confirmed this suspicion when we calculated hazards ratios for the patients who experienced discordant response or downstage without pCR (data not shown). As suspected, due to the heterogeneity of these groups, most of the hazards ratios failed to reach statistical significance and the cohort size within each stage-specific response was relatively small; thus, eliminating those 2 groups allowed for more streamlined analysis and reporting. While we recognize that some of the upstaged patients may be patients who received incomplete or inaccurate staging at diagnosis rather than patients who progressed through treatment, we chose to include upstage because progression in both the breast and axilla is relatively unambiguous, whereas the definition of a mixed, partial, or discordant response to NACT is difficult to ascertain. We recognize that downstage that falls short of overall, breast-only, and node-only pCR may also provide important prognostic information that merits further investigation, but this topic falls outside the scope of our study.
CONCLUSION
We believe ours to be the largest population-based study to evaluate the prognostic significance of overall pCR as well as anatomically limited pCR in breast cancer patients treated with NACT. We found that patients who are node-positive at presentation and achieve pCR have a comparable prognosis to those who are clinically node-negative at presentation. Furthermore, survival is improved even if pCR is limited to the breast or axilla, but the extent of this survival benefit is subtype-specific. These findings are especially relevant in the context of ongoing attempts to identify patients in whom pCR has been achieved and surgical resection can potentially be safely avoided. [32] [33] [34] [35] Finally, the results of our study can help inform the conversations and shared decision-making of clinicians caring for patients undergoing neoadjuvant therapy and can provide researchers with pragmatic, short-term endpoints for assessing the efficacy of treatments being evaluated as part of clinical trials.
DISCUSSANTS
Dr Tari A. King (Boston, MA):
I would like to thank the American Surgical Association for the opportunity to discuss this paper and congratulate the authors on a very nice presentation. Thank you also for providing me with the manuscript in advance.
In the manuscript the authors have provided a nice assessment of past and present views of breast cancer staging, highlighting our improved understanding of breast cancer biology and the prognostic significance of achieving a pCR to targeted therapy.
They have outlined the rationale for increased use of NACT in our breast cancer patients, which we have seen not only provides prognostic information but also response to therapy is now being used to tailor local therapy with trends toward increased use of neoadjuvant therapy to downstage the axillary lymph nodes, thereby avoiding the morbidity of node dissection.
Using data reported to the NCDB for patients with clinical T1-T3, clinical N0-N1 breast cancer treated with NACT and surgery from 2010 to 2014, the authors sought to accomplish 3 goals: to establish the rate of pCR, both complete and limited (defined as breast only or node only) by breast cancer subtype; to determine the association of this response, both complete and limited, with survival in node-positive patients; and to test the hypothesis that response to NACT is more important than presenting clinical stage.
As we saw, the analysis included over 20,000 patients with a median follow-up of 35.9 months, and the authors concluded that in patients achieving path CR, survival is driven by pCR and not presenting stage at diagnosis; such that node-positive and nodenegative patients do equally well if pCR is achieved. This finding supports the conduct of current clinical trials aimed at reducing the use of comprehensive nodal RT in patients who start out node positive and achieve a nodal path CR. This is a very important observation.
They have also demonstrated that in node-positive patients, limited pCR predicts survival for particular subsets. Specifically, breast-only pCR is associated with improved survival in the triplenegative breast cancer subset, but achieving a breast-only pCR was not associated with favorable outcomes in the other breast cancer subtypes, suggesting that any opportunity to achieve path CR in the highly aggressive triple-negative group is worthwhile for our patients.
In the HER2Àpositive subset, where we typically see the highest rates of pCR, achieving a limited anatomical path CR (breast only or node only) was not associated with a survival advantage, demonstrating the poor prognosis conferred by residual disease after neoadjuvant therapy in this subset and our need to continue to look for better strategies for these HER2Àresistant patients.
I have just a couple of questions for the authors.
In the overall analysis, pCR was not associated with survival among clinically node-negative patients with HR-positive HER2À positive disease. We know this disease subtype has very high rates of path CR and very good survival. Can you comment on why there may not be a relationship between path CR and survival in this cohort?
Also, as you showed in your Cox proportional hazards model for OS, the type of surgery, specifically mastectomy, was associated with inferior OS. Now, I note that in your manuscript you commented that you did not include some clinical factors in your model to avoid overfitting, and tumor size in particular, was not included, which is often what is driving the decision toward mastectomy. Can you elaborate on why you chose not to include tumor size and how do you interpret the finding that mastectomy is associated with inferior OS? I think this is particularly important, as we continue to see the trend toward more women choosing mastectomy or choosing bilateral mastectomy for the management of unilateral breast cancer.
Finally, having had the opportunity to review the supplementary files of your adjusted hazard ratio models for OS by subtype, in most of the analyses, you do not see the same relationship with mastectomy and inferior OS. Can you please comment on your interpretation of this interplay between surgery, tumor biology, and response to therapy?
Thank you again for the opportunity to review this paper and congratulations on your work.
Response from Oluwadamilola ''Lola'' Fayanju:
Many thanks to Dr King for her thoughtful commentary. With regards to the triple-positive phenotype -specifically, the HR-positive, HER2Àpositive patients with node-negative disease -these patients represent people who start off with very good biology and also have a plethora of treatment options. Therefore, they have as much in their favor as could possibly be expected with breast cancer diagnosis.
As a result, pCR is less critical for these patients having a good long-term outcome. In our study, we did not have sufficient events or sufficient length of follow up to see basically any type of significant survival detriment in that group. So, yes, indeed, because these patients have good biology and good treatment options, and there was not a very long period of time over which to observe them, there was insufficient evidence to establish a relationship between path CR and OS.
With regards to the finding of mastectomy being associated with worse OS, this has actually been seen in other population-based analyses even if it has not been demonstrated in clinical trials; notably, studies examining the California Cancer Registry have shown that mastectomy seems rather inexplicably to be associated with lower OS. We think, in part, this is because there are confounding factors that are not accounted for that allow for there to be sicker patients with worse disease systematically getting mastectomy. In particular, we do not have an intermediate staging opportunity between diagnosis and pathologic stage; that is, we do not know what information goes into people's choosing mastectomy once they have completed their systemic therapy.
Thank you for bringing up the idea that tumor size might be an important component of that relationship. Tumor size, of course, is calculated in the NCDB on the pathological specimen, unless there is no surgery performed. So, it is information that is only available after surgery. But, nonetheless, we could consider including tumor size in the regression model or to see whether or not that would influence mastectomy or perhaps erase the effect that was seen.
We will say that we did not initially include tumor stage in our multivariate analyses because we were concerned about the fact that we use tumor stage in part to define a response to chemotherapy, and we wanted to avoid the collinearity that might be seen by including both tumor stage and response to chemotherapy in the same analysis. But we will take into consideration the tumor size recommendation. And if it is not collinear with other covariates, including the type of breast surgery, we can include that in our analysis.
Finally, with regards to axillary surgery, there is not very reliable coding on ALND in the National Cancer Database. As a result, we and many others have used proxy estimations of axillary surgery, namely, deciding that lymph node yield cut into tertiles of 1 to 5, 6 to 9, and greater than 10, would be proxies for sentinel lymph node biopsy or ALND.
Of course, lymph node yield does not reveal the intention of the surgeon, and we know that NACT systematically downstages the axilla and makes the retrieval of lymph nodes more difficult. Accordingly, it is difficult for us to know whether the low lymph node yield we see with particular subtypes represents patients' inappropriately not getting axillary dissections or whether it just reflects the chemosensitivity of those tumors. And, indeed, we did observe that triple-negative patients had the lowest yield of lymph nodes, and they are often the most chemosensitive; HR-positive, HER2Ànegative patients had the highest yield, and those are generally more chemoresistant.
Dr Frederick Greene (Charlotte, NC):
I have no disclosures except that I am passionate about use of the NCDB, so thank you for using it in this analysis.
In the language of TNM, complete response is defined as absence of invasive disease. Residual DCIS, therefore, is still defined as complete response.
Since cancer registrars are taught to always code for in situ disease even though the invasive component disappears, in your analysis of these subsets, were you able to define those cases that had only in situ cancer remaining? It would be important to know how residual in situ cancer, in the absence of invasive disease, affects OS. Did you look at that subset which is fairly large in the NCDB?
Thank you, Dr Greene, for your question. We deliberately excluded patients who had either preoperative DCIS or patients who were found to have DCIS after surgery and neoadjuvant treatment. There is some evidence that, although DCIS has historically been included in definitions of path CR, it is actually a different actor; that having ypTis, that is, in situ disease after neoadjuvant therapy, is not prognostically similar to having no tumor whatsoever. In general, several studies out of the German group by von Minckwitz have shown that there is a differential prognosis between DCIS being residually left in the tumor bed versus there being no tumor. So, we excluded those patients in order to allow for a cleaner analysis to see truly whether or not if you isolated pCR, as defined as no tumor left in a particular compartment, either the breast or axilla, what the relationship was between that and survival. We felt that including DCIS -given the possibility of that being a response to chemotherapy -is not quite the same as the complete eradication of disease. We thought excluding it would allow for a cleaner analysis with more definitive conclusions.
Dr Funda Meric-Bernstam (Houston, TX):
Really nice work. A few questions. I am not as familiar with this database, but I presume that you do not have the granularity to know whether these were clinical examination N1s versus cytologically proven N1s. How do you think that would impact your numbers?
Second, there has been evolution in the last year of adjuvant therapies available, especially for HER2Àpositive disease, and, of course, for ER-positive disease, a lot of new adjuvant therapies are being tested. How would you use these data to help provide guidance?
Third, the surgical management of the axilla is changing for N1 disease. There is now a lot of momentum surrounding targeted axillary dissections, which may help identify the nodes that were positive upfront and maybe would have been missed on gross pathological assessment. But of course, when a patient has a node-only pCR, one would wonder if it is a false negative. I was wondering how you think with the new surgical approaches your results will change.
Thank you, Dr Meric. First of all, with regards to how nodal status is defined in the NCDB, it is a combination of percutaneously obtained tissue, so if a patient has a lymph node positive based on needle biopsy; exam findings; as well as imaging. And that is how clinical nodal stage is ascribed.
Of course, because there is no central pathologic or radiologic review, what is contained in the NCDB is dependent on how things are reported by the contributing institutions. So, that is the definition of clinical nodal staging, as provided by the NCDB that we go by. It is the most comprehensive source of this type of information, but it is indeed limited by the accuracy of the reporting institutions.
Your second question was about adjuvant therapy and how the findings impact decision-making. As you all saw, HER2Àpositive disease responds beautifully to neoadjuvant systemic therapy, and that has been a huge development in breast cancer management. Indeed, it has allowed us to convert patients with palpable nodes, clinically node-positive disease to having pCR. I think the picture can only get better. I think, frankly, HER2Àpositive disease offers a vision of what the future could look like with aggressive breast cancer, if only we could achieve similarly effective types of systemic therapy for the other subtypes.
I think we will continue to refine our sense of what success looks like in breast cancer. The truth of the matter is most people with breast cancer do well, but for those patients who do not do wellthose with triple-negative disease, those with significant node-positive disease, those with HER2Àpositive disease in the past -can we go the way of HER2Àpositive disease and potentially avoid more extensive surgery in patients who currently need a lot of treatment for their disease?
Your third question was about targeted axillary dissection, which has been an important development in the management of node-positive breast cancer. Again, I think pCR gives us more assurance in patients who undergo targeted axillary dissection because we know at least that the nodes that were previously biopsied are again being sampled and fully examined biologically, histologically.
I think that targeted axillary dissection will only help us in that it will prevent the finding of false-negative reassurance. We know that pathologic response is not the endgame. We know that even in patients who achieve path CR, there is still a danger for relapse, particularly in patients with triple-negative disease and other more aggressive variants. So, to the extent that we can be smarter about our surgery and get more accurate information about our staging after chemotherapy, I think that findings of path CR will be only more and more reassuring as our surgeries become more precise.
Dr Edward M. Copeland, III:
Why when you get a pCR do you get a better survival?
Response from Oluwadamilola ''Lola'' Fayanju: Response from Oluwadamilola ''Lola'' Fayanju: pCR, is more likely to be seen, actually ironically, in patients who otherwise would have very high Oncotype scores. That is a very good question. We know that to be true, in general, with higher grade and either triple-negative or HER2Àpositive disease; indeed, those patients, if they do not have any HR-positive component, would not even get an Oncotype.
But in patients who are HR-positive and potentially grade 3, patients in whom we would expect the higher Oncotype, I suspect we would also hopefully see a high path CR. It is kind of a nice marriage between aggressive biology but actually fairly chemosensitive biology. So, I would imagine that high Oncotype would also be associated with a greater likelihood of path CR, which would be good for those patients.
